Synthesis and Biological Evaluation of Some Pyrrolo[2,3-d]pyrimidines
Mosaad S. Mohamed
Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt
Search for more papers by this authorMagdy E. A. Zaki
Photochemistry Department, National Research Centre, Dokki, Cairo, Egypt. Fax: +20 23 370-931
Search for more papers by this authorSamar S. Fatahala
Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt
Search for more papers by this authorMosaad S. Mohamed
Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt
Search for more papers by this authorMagdy E. A. Zaki
Photochemistry Department, National Research Centre, Dokki, Cairo, Egypt. Fax: +20 23 370-931
Search for more papers by this authorSamar S. Fatahala
Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt
Search for more papers by this authorAbstract
Pyrrolo[2,3-d]pyrimidine and tetrazolopyrimidine derivatives 2a, b–5a, b were prepared. Also, acyclic and cyclic C-nucleosides 7a, b–12a, b were prepared by treating compound 6 with some aldoses. All prepared products were tested for antiviral activity against hepatitis-A virus (HAV, MBB-cell culture adapted strain) and herpes simplex virus type-1 (HSV-1). Plaque reduction infectivity assay was used to determine virus count reduction as a result of treatment with tested compounds. Compound 2a showed the highest effect on HAV, while compound 11b showed the highest effect on the HSV-1 virus.
References
- 1 E.De Clercq, J.Balzarini, M. J.Robins, J. Med. Chem. 1987, 30, 481–486.
- 2 P. K.Gupta, J. C.Drach, L. B.Townsend, J. Med. Chem. 1989, 32, 402–408.
- 3 J. G.Jacobson, T. E.Renau, M. R.Nassiri, D. G.Sweier, Antimicrob. Chemother. Agents 1999, 43, 1888–1894.
- 4 E.De Clercq, Nucleosides, Nucleotides 2004, 23, 457–470.
- 5 Y. A.Ibrahim, A. H. M.Elwahy, Adv. Heterocycl. Chem. 1996, 65, 235–281.
- 6 Z. A.Hozien, F. M.Atta, Kh.Hassan, M. A. A.Abdelwahab, S. A.Ahmed, Synth. Comm. 1996, 26, 3733–3742.
- 7 K. A.Ismail, O. M.Aboulwafa, E.Koreish, Farmaco 1995, 50, 611–616.
- 8 M. A. E.Shaban, M. A. M.Taha, A. Z.Nasr, A. E. A.Morgaan, Pharmazie 1995, 50, 784–788.
- 9 G. A.El-Hiti, Alex. J. Pharm. Sci. 2000, 14, 37–40.
- 10 N.Rashed, A.El Nemr, E. S. H.El-Ashry, Spectrosc. Lett. 1996, 26, 1817–1838.
- 11 N.Rashed, H.Abdel-Hamid, E.Ramadan, E. S. H.El-Ashry, Nucleosides, Nucleotides 1996, 17, 1373–1384.
- 12 M. A. E.Shaban, M. A. M.Taha, Bull. Chem. Soc. Jpn. 1989, 62, 2701–2708.
- 13 R. J.Shuhadolink, C-Nucleosides antibiotics, Wiley Interscience, New York, 1970.
- 14 E. S. H.El-Ashry, N.Rashed, A.Mousaad, J. Carbohyd. Chem. 1987, 6, 599–607.
- 15 Y. A.Alsoud, N. A.Almasoudi, Arch. Pharm. 1999, 332, 143–144.
- 16 A.Hamed, E. R.Abo-Amaym, E. S. H.El-Ashry, Nucleosides, Nucleotides 1998, 17, 1385–1407.
- 17 L. F.Awad, E. S. H.El-Ashry, Carbohyd. Res. 1998, 312, 9–22.
- 18 C.Turk, J.Svete, A.Golobic, L.Golic, B.Stanovnik, J. Heterocycl. Chem. 1998, 35, 513–518.
- 19 M. A. E.Shaban, A. Z.Nasr, Adv. Heterocycl. Chem. 1997, 68, 223–432.
- 20 M. A. E.Shaban, A. E. A.Morgaan, Adv. Heterocycl. Chem. 1999, 70, 131–176.
- 21 E. S. H.El-Ashry, Y.El-Kilany, Adv. Heterocycl. Chem. 1998, 69, 129–215.
- 22 J. L.Kelley, J. E.Kelsey, W. R.Hall, J. Med. Chem. 1981, 24, 753–756.
- 23 J. L.Kelley, M. P.Krochmal, H. J.Schaeffer, J. Med. Chem. 1981, 24, 472–474.
- 24 M. A.Mohamed, A. E.Rashad, M. E. A.Zaki, S. S.Fatahala, Acta Pharm. 2005, 55, 237–249.
- 25 A. H.Shamroukh, A. E.Rashad, H. H.Sayed, Phosphorus, Sulfur, Silicon 2005, 180, 2347–2360.
- 26
M. E. A.Zaki,
H. A.Soliman,
O. A.Heikal,
A. E.Rashad,
Z. Naturfor.
2006,
61c,
1–5.
10.1515/znc-2006-1-201 Google Scholar
- 27 A. E.Rashad, O. A.Heikal, A. O. H.El-Nezhawy, F. M. E.Abdel-Megeid, Heteroatom Chem. 2005, 16, 226–234.
- 28 F. M. E.Abdel-Megeid, N. A.Hassan, M. A.Zahran, A. E.Rashad, Sulfur Lett. 1998, 21, 269–284.
- 29 A. E.Rashad, M. A.Ali, Nucleosides, Nucleotides 2006, 17, 17–28.
- 30 R. S.Farag, A. S.Shalaby, G. A.El-Baroty, N. A.Ibrahim, et al., Phytother. Res. 2004, 18, 30–37.